TrialJournal of diabetes investigation2021

Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.

Kyu Yong Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.